Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that activate these survival genes in specific sites of metastasis. Estrogen receptor-negative breast cancer cell line MDA-MB435 and two metastatic sublines derived from lung (435L) and brain (435B) were analysed for the expression of members of the Bcl-2 family of apoptosis regulators. The levels of Bcl-2 were higher in the metastatic sublines than in parental cells, which correlated with the activation of Stat3, but not with the expression and/or activation of known bcl-2 transcription factors (CREB and WT1). In the brain subline, both expression of Bcl-2 and Stat3 activation were induced by epidermal growth factor and abrogated after treatment with kinase inhibitors specific for epidermal growth factor receptor or Jak2. Furthermore, transfection of 435B with a dominant-negative Stat3 markedly reduced the expression of Bcl-2 protein, whereas transient expression of a constitutively active Stat3 increased Bcl-2 in parental 435 cells. In addition, blockade of Stat3 activation by treatment with epidermal growth factor receptor and Jak2 kinase inhibitors or transfection with a dominant negative Stat3, sensitizes 435B cells to chemotherapy-induced apoptosis. Our data suggest that an increased activation of the Stat3 -Bcl-2 pathway in estrogen receptor-negative metastatic breast cancer cell lines confer a survival advantage to these cells and contribute to their chemoresistance.
Introduction
Aberrations in gene expression and/or protein activity by cancer cells leads to transformation, invasion, and eventually dissemination and attachment in the organ of metastasis. In addition, for a tumor cell to become metastatic, it must be able to survive in the circulation and respond appropriately to the new environment. This includes being able to utilize growth factors from the organ of metastasis for the benefit of the secondary tumor. At early stages of metastatic progression, paracrine and autocrine mechanisms may dominate the growth and survival signals. In contrast, at later stages metastatic cells may become completely autonomous (Nicolson, 1993) . Breast cancers often progress from a hormone-dependent, non-metastatic phenotype, to a hormone-independent, antiestrogen-and chemotherapy-resistant phenotype with highly invasive and metastatic growth properties. Moreover, it has been suggested that decreased apoptosis may play an important role in the biological aggressiveness of breast cancer (Wu, 1996) , which is consistent with other studies indicating that apoptosis is one of the main homeostatic mechanisms designed to eliminate misplaced cells and inhibit metastatic dissemination (Glinsky et al., 1997; Jaattela, 1999) .
Mammary gland development is characterized by changes in the expression of members of the Bcl-2 family of apoptosis regulators. To this end, it has been shown that Bcl-2 gain-of-function increases cell survival during the two stages of mammary gland involution, suggesting an impact of Bcl-2 on mammary epithelial cell survival (Schorr et al., 1999) . Interestingly, Bcl-2 overexpressing clones from the human breast cancer cell line MCF7 ADR injected into nude mice induce a significantly higher number of lung metastases compared to the control transfectant clone, suggesting that bcl-2 overexpression may increase the invasive capacity of breast cancer cells (Del Bufalo et al., 1997) . Consistent with this, Bcl-2 expression has been strongly associated with both apoptosis loss and presence of lymph node metastases in tumor samples from patients with ductal breast carcinomas (Sierra et al., 1996) , which indicates that inhibition of apoptosis might facilitate the acquisition of additional genetic alterations associated to disease progression . Other Bcl-2 family members have also been associated with breast cancer. Bax, a promoter of apoptosis, is expressed in high amounts in normal cell lines and breast tissue but is almost absent in cancer cell lines and malignant tissue (Bargou et al., 1995) . Moreover, Bcl-x L , as well as Bcl-2, are up-regulated in response to an overexpression of human epidermal growth factor receptor-2 (HER-2) in MCF7 cells, which may be associated with the enhanced survival of HER-2-overexpressing breast cancer cells (Kumar et al., 1996) . Despite these findings, relatively little is known about the molecular mechanisms that regulate the expression and function of the Bcl-2 family members in mammary carcinogenesis and metastasis.
In this study, we propose that the epidermal growth factor receptor (EGFR)-Stat3 -Bcl-2 pathway confers a survival advantage to metastatic estrogen receptor (ER)-negative breast cancer cell lines that renders these cells resistant to chemotherapy-induced apoptosis, and may also contribute to their metastatic phenotype.
Results

Expression of Bcl-2 and Bcl-x L in ER-positive and ER-negative breast cancer cell lines
It is not clear how normal signaling pathways controlling apoptosis in the human breast act in the development of tumors or in tumor progression. Among the apoptosis regulators, the anti-apoptotic proteins Bcl-2 and Bcl-x L have been mostly associated with ER-positive breast cancer cells (Krajewski et al., 1999; Perillo et al., 2000) . We first analysed the expression of both Bcl-2 and Bcl-x L at the mRNA and protein level in ER-positive (MCF-7 and BT474) and ER-negative (MDA-MB-231 and SKBR3) human breast cancer cell lines. As shown in Figure 1a , the levels of Bcl-2 mRNA and protein are low or undetectable in both sub-groups, whereas Bcl-x L is expressed in all cell lines, being the highest protein levels detected in BT474. 435 cells transfected with bclx L have been shown to increase their metastatic capacity when injected into immunodeficient mice . In order to study the endogenous expression of Bcl-2 and Bcl-x L in a model of metastasis, we analysed parental 435 cells and two sub-lines derived from brain (435B) and lung (435L) metastases in a nude mouse (Price et al., 1990; Sierra et al., 1997) . Figure 1b shows that the mRNA and protein levels of Bcl-x L are less than twofold higher in 435B and 435L than in the parental cell line. Interestingly, the levels of Bcl-2 increased 3 -5 times in metastatic cells, and the highest expression was found in 435B cells. The expression of other members of the Bcl-2 family either decreased (mcl-1) or remained constant (bax, bad) in the metastatic cell lines (Figure 1b) .
Activation of bcl-2 transcriptional regulators in 435 cell lines
As the expression of Bcl-2 was up-regulated in the metastatic cells, we searched for a transcriptional factor of the bcl-2 gene in 435 cell lines. The bcl-2 promoter contains a cAMP response element (CRE) that binds CRE binding protein (CREB) in response to estrogen in breast cancer cell lines (Dong et al., 1999) . Although 435 cells are ER-negative, we looked for a constitutive expression or activation of CREB. Figure  2a shows that creb mRNA levels remain constant in all three 435 cell lines. As postranslational modifications Figure 1 Expression of Bcl-2 family members in breast cancer cell lines. (a) Total RNA was purified from ER-positive (BT474, and MCF7) and ER-negative (MB231, and SKBR3) cells and subjected to RT -PCR analysis with primers specific for bcl-2 and bcl-x L . Plasmids containing bcl-2 or bcl-x L cDNAs were also amplified as positive controls. PCR products were electrophoresed onto a 2% agarose gel. gapdh mRNA was used as an amplification control. Western blot analysis of Bcl-2 and Bcl-x L proteins in the same cell lines (lower panels). Analysis of bcl-x L -transfected HL-60 cells was included as positive control. (b) The mRNA levels of bcl-2, bcl-x L , mcl-1, bax and bad were analysed by RT -PCR in parental MB435 cells (435) and metastatic variants (435L and 435B). Western blot analysis of Bcl-2 and Bcl-x L in MB435 cell lines (lower panels). The levels of b-Tubulin were analysed to assure equal loading such as phosphorylation regulate the activity of CREB (Wilson et al., 1996) we then analysed its capacity to bind to a consensus bcl-2 CRE sequence by EMSA (Figure 2b) , and the level of phosphorylated CREB by Western blot (Figure 2c ). Again, no differences were observed among the three cell lines. Another well studied transcriptional activator of bcl-2 is the tumor suppressor gene WT1 (Mayo et al., 1999) , which has been detected, sometimes at high levels, in advanced ER-negative breast tumors (Silberstein et al., 1997) . However, as shown in Figure 2a , no expression of wt1 mRNA could be detected in 435 cell lines. Recently, it has been suggested that Stat3 may be a transcriptional activator of bcl-2 in heart-derived U3A-ST1 cells (Stephanou et al., 2000) . In addition, Stat3 has been found to be constitutively activated in some breast carcinoma cell lines (Garcia et al., , 2001 , which prompted us to analyse the DNA-binding activity of Stat3 in 435 cell lines. Interestingly, the binding activity of Stat3 was significantly higher in 435L and 435B than in 435 parental cells, being the highest activity detected in 435B (Figure 3 ), which was consistent with the upregulated expression of Bcl-2 observed in this metastatic cell line.
EGFR and Jak2 tyrosine kinases induce activation of Stat3 and expression of Bcl-2 in metastatic 435 cells EGFR has been shown to increase the tumorigenic potential of transformed human mammary epithelial cells (Ma et al., 1998) , and its overexpression in breast cancer predicts for poor prognosis and is inversely correlated with expression of ER (Yarden et al., 2001) . Here, we analysed whether inhibition of the EGFR tyrosine kinase activity was able to down-regulate both activation of Stat3 and expression of Bcl-2 in metastatic breast cancer cells. We first analysed the expression of egfr mRNA and found that it was significantly higher in 435B than in 435L and parental 435 cells, whereas the levels of her2 mRNA, another member of the EGFR family associated to breast cancer, remained constant in all the cell lines ( Figure  4a ). Moreover, we showed that serum-starved 435B cells responded to exogenous EGF by up-regulating the expression of Bcl-2 protein after 48 h of treatment ( Figure 4b ). Then, 435B cells were treated with PD168393, a specific inhibitor of the EGFR tyrosine kinase (Fry et al., 1998) , and studied for the activation of Stat3 and the expression of Bcl-2 protein. Figure 5 shows that following 4 h treatment with the inhibitor, the DNA binding capacity of Stat3 was clearly reduced to a level similar to that observed when cells were incubated in the presence of AG490, an inhibitor of Jak2 tyrosine kinase that blocks activation of Stat3 in a number of cell systems. In addition, both inhibitors reduced the expression of Bcl-2 in 435B cells after 24 h Figure 2 Expression and activation of bcl-2 transcription factors in MB435 cell lines. (a) Total RNA was purified from parental 435 cells and metastatic variants and subjected to RT -PCR analysis with primers specific for creb, and wt1. Analysis of mRNA from K562 cells was included as positive control. PCR products were electrophoresed onto a 2% agarose gel. gapdh mRNA was used as an amplification control. (b) MB435 cells were analysed for the formation of CREB -DNA complexes by EMSA using a radiolabeled probe. For competition experiments, nuclear extracts were preincubated with 100-fold molar excess of unlabeled creb specific probe (100xSP) or unlabeled irrelevant DNA fragment (100xNSP). (c) MB435 cells were analysed for the presence of phospho-CREB by Western blot. The levels of b-Tubulin were also analysed to assure equal loading Figure 3 DNA binding activity of Stat3 in MB435 cell lines. The formation of Stat3 -DNA complexes was determined by an EMSA using a radiolabeled consensus probe. Nuclear extracts of 435B cells were preincubated with antibodies specific for Stat3 (+aSt3) or Stat5 (+aSt5) of treatment, whereas Bcl-x L was only slightly downregulated upon exposure to the EGFR kinase inhibitor ( Figure 5 ). Similar results were obtained with another EGFR kinase inhibitor, PKI166 (data not shown), recently described to inhibit growth and metastasis of human pancreatic carcinoma cells (Bruns et al., 2000) . To further confirm this EGF-induced survival pathway, 435B cells were starved of serum for 48 h and then treated with EGF in the presence or in the absence of kinase inhibitors prior to analysing the DNA binding activity of Stat3 and the levels of Bcl-2 protein. Figure 6 shows that in the absence of serum the activity of Stat3 is reduced, but following treatment with EGF this binding activity is similar to that of control cells. Interestingly, the presence of AG490 or PD168393 abrogated the EGF-induced binding of Stat3 to its consensus DNA sequence. Consistent with our previous data, the activity of Stat3 under all these conditions correlated with the levels of Bcl-2, thus the kinase inhibitors avoid the expression of this antiapoptotic protein in response to EGF (Figure 6 ).
Inhibition of the Stat3 transcriptional activity blocks the expression of Bcl-2 and sensitizes 435B cells to chemotherapy induced apoptosis To analyse whether Stat3 leads to the transcription of Bcl-2, we determined the effect of a dominant-negative Stat3 (Stat3DN) (Catlett-Falcone et al., 1999) , on the Bcl-2 expression and survival of 435B cells. Figure 7a shows a representative experiment in which cells are transfected with a vector expressing EGFP alone (pIRES -EGFP) or a vector encoding both EGFP and Stat3DN (pIRES -Stat3DN). After 24 h of transfection with pIRES -EGFP, 50.1% of the EGFP-positive cells expressed Bcl-2 as determined by flow cytometry with a specific antibody. In contrast, the great majority (about 90%) of the cells transfected with pIRES -Stat3DN that expressed EGFP were Bcl-2-negative. Furthermore, constitutively activated Stat3 At the indicated times, cells were harvested and analysed for the expression of Bcl-2 and Bcl-x L by Western blot. The levels of bTubulin were also analysed to assure equal loading. C, untreated control cells Figure 5 Regulation of the Stat3 -Bcl-2 pathway by tyrosine kinase inhibitors in 435B cells. Cells were cultured in the presence of PD168393 (PD) or AG490 (AG), two kinase inhibitors of EGFR and Jak2 respectively, and then analysed for the formation of Stat3 -DNA complex by EMSA using a radiolabeled probe (top), and for the expression of Bcl-2 and Bcl-x L proteins by Western blotting (bottom). The levels of b-Tubulin were also analysed to assure equal loading. C, untreated control cells Figure 6 Regulation of the Stat3 -Bcl-2 pathway by EGF in 435B cells. Cells were deprived of serum for 48 h and then either left untreated (7EGF) or cultured with EGF in the presence (+AG, +PD) or in the absence (7) of EGFR or Jak2 kinase inhibitors. Nuclear extracts were obtained after 4 h of treatment and analysed for the formation of Stat3 -DNA complex by EMSA (top). At 24 h of treatment the expression of Bcl-2 protein was analysed by Western blot (bottom). The levels of b-Tubulin were determined to assure equal loading. C, untreated control cells (Stat3-C) induced the expression of Bcl-2 in parental 435 cells (from 53.7 to 76.3% of Bcl-2-expressing cells) (Figure 7b ). Interestingly, morphological examination of EGFP positive cells transfected with pIRESStat3DN did not show evidences of apoptotic cell death which prompted us to study whether disruption of the Stat3 activation pathway could sensitize 435B cells to chemotherapy induced apoptosis. Figure 8a shows that following a 16 h treatment with taxol at concentrations of 5 -100 nM, 435B cells were more resistant to apoptosis than parental cells. The level of apoptosis induced by treatment with 10 nM taxol was as much as three times higher in parental than in 435B cells (Figure 8a) .
Then, we pretreated 435B cells with PD168393 before adding taxol (Figure 8b) , and interestingly enough this EGFR inhibitor completely abrogated the chemoresistance of 435B cells at a concentration that does not induce apoptosis by itself but significantly reduces the activation of Stat3 and the expression of Bcl-2 ( Figure 5) . A similar result was obtained when cells were treated with 1 mM adriamycine (Figure 8b ). The Jak2 kinase inhibitor AG490 reduced also the chemoresistance to taxol and adriamycine although at a lower level than that obtained with the EGFR inhibitor (data not shown). An increase in chemotherapy-induced apoptosis was also obtained when 435B cells were transfected with dominant negative Stat3. Following treatment with taxol, the number of apoptotic (TUNEL positive) cells within the Bcl-2 negative cell population increased threefold when compared to untreated cells (data not shown). In order to confirm these results, we analysed the response to taxol and adriamycine of another ERnegative breast cancer cell line, SUM-159 in which we detected an up-regulated Stat3 -Bcl-2 pathway ( Figure  8c,d) and found a level of chemotherapy-induced apoptosis resistance similar to that found in 435B cells, which was reverted after treatment with PD168393 (Figure 8b ). These data suggest that the Stat3 -Bcl-2 survival pathway may play an important role in the resistance of ER-negative metastatic breast cancer cells to chemotherapeutic drugs.
Discussion
We have focused our attention to the regulation of apoptosis in ER negative breast cancer cells, which tend to be more agressive than carcinoma cells expressing steroid hormone receptors. In addition, ER-negative ductal carcinoma in situ express EGFR and HER-2 (Bundred et al., 2001) which are suggested to be the main receptor pathway associated with epithelial proliferation and survival in the human breast.
Among different members of the Bcl-2 family of apoptosis regulators, we found that the levels of Bcl-2 were higher in metastatic (435L, 435B) than in parental (435) ER-negative breast cancer cells. The expression of this anti-apoptotic gene can be induced by the estrogen receptor through multiple enhancer elements in breast cancer cells (Dong et al., 1999) . However, little is known about the bcl-2 transcriptional pathways in ER-negative breast cancer cells. We have shown that CREB and WT1 which transactivate the bcl-2 gene in a number of systems are unlikely candidates to account for the expression of bcl-2 in 435 cells. On the contrary, we found that activation of Stat3 was significantly higher in metastatic cells, which is consistent with previous data showing that a constitutive activation of Stat3 participates in growth regulation of breast carcinoma cells (Garcia et al., 2001) . Recently, it has been suggested that Stat3 may be a transcriptional activator of bcl-2 in heart-derived U3A-ST1 cells (Perillo et al., 2000) and in nonHodgkin's lymphoma cells (Alas and Bonavida, 2001) . We show here that Stat3 regulates the bcl-2 gene expression by using inhibitors of Stat3 activation, a dominant-negative Stat3, and a constitutively active form of Stat3, and that this survival pathway is triggered by the EGFR. We also suggest that Jak2 kinase plays a role in the activation of the Stat3 -Bcl-2 pathway, and that it is activated, at least in part, by EGFR. In support of this, it has been shown that EGF strongly stimulates tyrosine phosphorylation of both EGFR and Jak2 tyrosine kinases in PC12 cells (Zhong and Minneman, 1999) , and that Jak2 may become activated by homodimerization of the EGFR in an interleukin-3-dependent cell line (Nakamura et al., 1996) . Thus, EGFR and Jak2 may be in the same signaling pathway that induces expression of bcl-2 via Stat3 in metastatic 435 cells. EGFR is one of the receptors most commonly associated with human tumors, and has been shown to correlate with the metastatic progression of breast cancer (Harris et al., 1992; Wells, 1999) . We found that in the absence of serum, Bcl-2 protein is down-regulated in 435B cells; however, treatment of serum-starved cells with EGF increases both the expression of Bcl-2 and the activation of Stat3. These data suggest that serum may contain EGF at a concentration enough to activate this survival pathway, which is consistent with the elevated expression of the EGF receptor in 435B, that may render metastatic cells more sensitive to EGF. Alternatively, other serum growth factors may overlap with the survival signals triggered by EGF. In line with this, the insulin-like growth factor I has been implicated in breast cancer (Bartucci et al., 2001) and activates Stat3 in different cell systems (Zong et al., 2000) . Although the activity of this growth factor has been mostly associated to ER-positive cells (Bartucci et al., 2001) we can not rule out its participation in regulating Stat3 in 435B cells.
Bcl-2 protein expression is elevated in tissue samples from patients with residual breast tumor after the completion of treatment (Ellis et al., 1998) , which indicates that Bcl-2 may be associated with chemoresistance in breast cancer cells. Interestingly, we found that 435B cells are more resistant to chemotherapyinduced apoptosis than parental 435 cells. Furthermore, blockade of Stat3 activation sensitizes 435B cells to taxol and adriamycine. Consistently, MB-435 cells transfected with HER-2, which also activates Stat3 (Fernandes et al., 1999) , are more chemoresistant than the control cells (Yu et al., 1996) . These data suggest that the EGFR-dependent overactivation of the Stat3 -Bcl-2 survival pathway may render metastatic breast cancer cells resistant to chemotherapeutic drugs.
Materials and methods
Cell lines and reagents
ER-positive (MCF7 and BT474) and ER-negative (MDA-MB231 and SKBR3) human breast cancer cell lines were maintained in RPMI 1640 medium (Biochrom KG, Berlin, Germany) supplemented with 10% fetal calf serum (Flow Laboratories, Irvine, CA, USA). The ER-negative MDA-MB435 (435), MDA-MB435L (435L) and MDA-MB435B (435B) cell lines (Price et al., 1990) were incubated in DMEM/HAM's F-12 (Biochrom KG) supplemented with 10% fetal calf serum. SUM-159 was grown in DMEM/HAM's F-12 supplemented with 5% fetal calf serum, 5 mg/ml insulin, and 1 mg/ml hydrocortisone (both from SIGMA, St. Louis, MO, USA). When indicated, cells were treated with the Jak2 tyrosine kinase inhibitor, AG490 at a concentration of 40 mM, or the EGFR tyrosine kinase inhibitor PD168393 at 2 mM (both products were from Calbiochem, Schwalbach, Germany). At different time intervals, treated cells were analysed for protein expression and protein-DNA binding activity. 435B cells were incubated in the absence of serum for 48 h and then treated with 10 ng/ ml EGF (SIGMA) for various times. In some experiments, 435 and 435B cells were treated with taxol or adriamycine at different concentrations for 16 h, and then analysed for apoptotic cell death. Apoptosis was determined by a quantitative analysis of histone-associated DNA fragments using an enzyme-immunoassay (ELISA) kit (Roche, Mannheim, Germany), and further confirmed by DNA content using a FACScan, which correlates the percentage of hypodiploid cells with the extent of apoptosis (Horita et al., 2000) .
Electrophoretic mobility shift assay (EMSA)
Cells were cultured for 4 h in the presence or in the absence of tyrosine kinase inhibitors and then lysed as previously described (Silva et al., 1999) . Nuclear extracts (5 -10 mg of total protein) were incubated with a 32 P-labeled doublestranded DNA probe containing consensus sequences for stat3 (5'-gagcttcatttcccgtaaatcccta) or creb (5'-ggaaccgtgtgacgttacgca). Samples were run on a 5% non-denaturing polyacrylamide gel in 200 mM Tris-borate, 2 mM EDTA. Gels were dried and visualized by autoradiography. Supershifts were performed using rabbit polyclonal antibodies specific for Stat3 or Stat5 (Santa Cruz). For competition assays, nuclear extracts containing equal amounts of total protein were pre-incubated with 100-fold molar excess of either unlabeled creb probe or unlabeled irrelevant DNA fragment.
Immunoblotting
The expression of Bcl-2 and Bcl-x L proteins were determined by Western blotting as previously described (Benito et al., 1996) . Proteins (30 -60 mg) were separated on a 12% polyacrylamide gel, and transferred to nitrocellulose. Blots were blocked with 3% bovine serum albumin and incubated with rabbit anti-Bcl-x (Transduction Lab., Lexington, KY, USA), and anti-phospho-CREB (Cell Signaling Technology, Beverly, MA, USA), or mouse anti-Bcl-2 (Transduction Lab.), and anti-b-Tubulin antibodies (SIGMA), and then incubated with goat anti-rabbit or anti-mouse antibodies conjugated to alkaline phosphatase (SIGMA). Bound antibody was detected by a chemiluminescence system (Tropix).
RT -PCR analysis
Total RNA was prepared using TRIZOL reagent (GIBCO -BRL). To assess mRNA expression, a semiquantitative reverse transcriptase PCR (RT -PCR) method was used as previously described (Benito et al., 1996) . The generated cDNA was amplified by using primers for human bcl-x, bcl-2, gapdh (Benito et al., 1996) , bad (5'-gagccgagtgagcaggaag-3' and 5'-cgatcccaccaggactgga-3'), bax (5'-ctggacagtaacatggagctgc-3' and 5'-tctgatcagttccggcaccttg-3'), creb (5'-catggatctggagccgagaa-3' and 5'-gaacaacaacttggttgctgg-3'), egfr (5'-cttcttgcagcgatacagctc-3' and 5'-atgctccaataaattcactgc-3'), her2 (5'-tcgctcacaaccaagtgagg-3' and 5'-gcagtgcagctcacagatgc-3'), mcl-1 (5'-cgctggagattatctctcgg-3' and 5'-tgatgccaccttctaggtcc-3'), and wt1 (5'-agcccgctattcgcaatca-3' and 5'-ggtcatgcattcaagctgg-3'). The PCR conditions were optimized to get semi-quantitative data within the linear range of amplification. After 20 (gapdh), 25 (bcl-x, bad, creb, her2, mcl-1, wt1) or 28 (bcl-2, bax, egfr) amplification cycles, the expected PCR products were size fractionated onto a 2% agarose gel and stained with ethidium bromide.
Transfection and flow cytometry analysis 435B cells were transfected with either the vector encoding only enhanced green fluorescence protein (EGFP), pIRES -EGFP, or the same vector encoding both EGFP and dominant negative Stat3b, pIRES -Stat3b (Catlett-Falcone et al., 1999) . Parental 435 cells were transiently co-transfected with pIRES -EGFP and either a constitutively active form of Stat3 (Stat3-C, bridged by two cysteines instead of phosphotyrosines) (Bromberg et al., 1999) or the empty vector. Cells ( 3610 5 ) were plated and incubated with plasmid DNA (5 mg) mixed with 7.5 ml SuperFect reagent (Qiagen, Germany). After 24 to 36 h of transfection, cells expressing the green fluorescence protein were analysed for the expression of Bcl-2 as previously described (Benito et al., 1995) by flow cytometry using a FACScan analyser (Becton Dickinson, San Jose, CA, USA).
In some experiments, 435B cells were transfected with pIRES-Stat3b in the presence or in the absence of taxol and after 24 -36 h of transfection, the number of apoptotic cells was determined in the EGFP positive population by terminal deoxynucleotidyl transferase (TdT)-mediated d-UTP-biotin nick end-labeling (TUNEL), and propidium iodide uptake as described previously (Sanz et al., 2001) .
